Has Rosa Navarro, MD received payments from drug or device companies?

Yes. Drug and device makers reported $31,986 in general payments to Rosa Navarro, MD across 238 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rosa Navarro, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rosa Navarro, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rosa Navarro, MD

Interventional Pain Medicine · Chula Vista, CANPI 1083691802

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $23,902 of the $31,986 with a category attached, or 74.7%. Medtronic accounts for 87.9% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $12,988 and has fallen 95.3% since, to $615 in 2025.

$31,986in general payments, 2019–2025

Across 238 payments — averaging $134.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$28K
Vertiflex, Inc.$851
Boston Scientific$547
Stimwave Technologies Incorporated$523
Abbott$395
Teva Pharmaceuticals USA, Inc.$380
plus $1K from 16 others

$77,047in research payments, 2019–2025

Across 20 payments — averaging $3852.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$70K
Nevro Corp.$7K

What the payments were for

Speaking & faculty fees$23,90275%
Travel & lodging$1,9206%
Food & beverage$6,16419%
Education$00%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	110	$28,119
Vertiflex, Inc.	7	$851
Boston Scientific	20	$547
Stimwave Technologies Incorporated	7	$523
Abbott	8	$395
Teva Pharmaceuticals USA, Inc.	34	$380
AbbVie(2 entities)	13	$273
Nevro Corp.	8	$245
Amgen	5	$110
Vertos Medical, Inc.	2	$104
Lilly USA, LLC	7	$103
Si-bone, Inc.	2	$61
SPR Therapeutics, Inc	3	$59
Biohaven Pharmaceutical Holding Company Ltd.	2	$40
Pfizer	2	$40
Impel Pharmaceuticals Inc.	2	$33
Merz North America, Inc.	1	$20
Alnylam Pharmaceuticals Inc.	1	$20
Novartis	1	$19
AstraZeneca	1	$17
Nalu Medical, Inc.	1	$14
Assertio Therapeutics, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ADAPTIVESTIM$10,000
INTELLIS ADAPTIVESTIM$8,913
INTELLIS$6,661
Superion ISS$672
Vanta$250
INCEPTIV$147
GENERAL PAIN MANAGEMENT$123
Senza Spinal Cord Stimulation System$121
RESTORE$118
AJOVY$114

How this compares

$31,986 in reported general payments places this provider in the 85th percentile of 188 interventional pain medicine providers in California.

See all interventional pain medicine providers in California →

Medicare billing

Part B allowed, 2024

$214,656

Medicare patients

235

Services billed

5,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Pregabalin	144	$3,988
Gabapentin	155	$1,013
Cephalexin	21	$199
Baclofen	26	$132
Ibuprofen	25	$120
Cyclobenzaprine Hcl	16	$51
Meloxicam	27	$49
Tramadol Hcl	16	$37

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Chula Vista

Michael Verdolinla Mesa$507K
Tim LeierRancho Mirage$449K
Jonathan GrossmanVisalia$404K
Kasra MaasumiRancho Santa Margarita$388K
Andrew GermanovichRancho Mirage$333K
David LeeYorba Linda$257K
Standiford HelmOrange$254K
Patrick BuchananCamarillo$219K
Chau VuSanta Rosa$141K
Phillip LimBuena Park$127K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →